ACH-3102: Interim Phase IIa data

Interim data from 5 evaluable patients in an open-label Phase IIa trial showed that oral ACH-3102 plus ribavirin led to an RVR, defined as HCV RNA levels <25 IU/mL at week 4, in 80% of patients. ACH-3...